Literature DB >> 21116050

Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome.

Elizabeth Head1, Eric Doran, Mihaela Nistor, MaryAnn Hill, Frederick A Schmitt, Richard J Haier, Ira T Lott.   

Abstract

Adults with Down syndrome (DS) are at risk for developing Alzheimer's disease (AD). While plasma amyloid-β (Aβ) is known to be elevated in DS, its relationship to cognitive functioning is unknown. To assess this relationship, samples from two groups of subjects were used. In the first group, nondemented adults with DS were compared to: 1) a group of young and old individuals without DS and 2) to a group of patients with AD. Compared to these controls, there were significantly higher levels of plasma Aβ in nondemented adults with DS while AD patients showed lower levels of plasma Aβ. A larger second group included demented and nondemented adults with DS, in order to test the hypothesis that plasma Aβ may vary as a function of dementia and Apolipoprotein E (ApoE) genotype. Plasma Aβ levels alone did not dissociate DS adults with and without dementia. However, in demented adults with DS, ApoE4 was associated with higher Aβ40 but not Aβ42. After controlling for level of intellectual disability (mild, moderate, severe) and the presence or absence of dementia, there was an improved prediction of neuropsychological scores by plasma Aβ. In summary, plasma Aβ can help predict cognitive function in adults with DS independently of the presence or absence of dementia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21116050      PMCID: PMC3219221          DOI: 10.3233/JAD-2010-101335

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  46 in total

1.  Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment.

Authors:  Marzia Pesaresi; Carlo Lovati; Pierluigi Bertora; Enrico Mailland; Daniela Galimberti; Elio Scarpini; Pierluigi Quadri; Gianluigi Forloni; Claudio Mariani
Journal:  Neurobiol Aging       Date:  2006-04-25       Impact factor: 4.673

2.  Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

Authors:  P D Mehta; T Pirttilä; S P Mehta; E A Sersen; P S Aisen; H M Wisniewski
Journal:  Arch Neurol       Date:  2000-01

3.  Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism.

Authors:  Y M Kuo; T A Kokjohn; M D Watson; A S Woods; R J Cotter; L I Sue; W M Kalback; M R Emmerling; T G Beach; A E Roher
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 4.  Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Authors:  Kaj Blennow
Journal:  NeuroRx       Date:  2004-04

5.  Plasma levels of amyloid beta 40 and 42 are independent from ApoE genotype and mental retardation in Down syndrome.

Authors:  S Cavani; A Tamaoka; A Moretti; L Marinelli; G Angelini; S Di Stefano; G Piombo; V Cazzulo; S Matsuno; S Shoji; Y Furiya; D Zaccheo; F Dagna-Bricarelli; M Tabaton; H Mori
Journal:  Am J Med Genet       Date:  2000-11-27

Review 6.  Down syndrome and Alzheimer's disease: a link between development and aging.

Authors:  I T Lott; E Head
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2001

7.  Dementia in people with Down's syndrome.

Authors:  J Tyrrell; M Cosgrave; M McCarron; J McPherson; J Calvert; A Kelly; M McLaughlin; M Gill; B A Lawlor
Journal:  Int J Geriatr Psychiatry       Date:  2001-12       Impact factor: 3.485

8.  Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome.

Authors:  N Schupf; B Patel; W Silverman; W B Zigman; N Zhong; B Tycko; P D Mehta; R Mayeux
Journal:  Neurosci Lett       Date:  2001-04-06       Impact factor: 3.046

9.  Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain.

Authors:  M Nistor; M Don; M Parekh; F Sarsoza; M Goodus; G E Lopez; C Kawas; J Leverenz; E Doran; I T Lott; M Hill; E Head
Journal:  Neurobiol Aging       Date:  2006-08-09       Impact factor: 4.673

10.  Plasma Abeta levels do not reflect brain Abeta levels.

Authors:  Stefanie H Freeman; Susan Raju; Bradley T Hyman; Matthew P Frosch; Michael C Irizarry
Journal:  J Neuropathol Exp Neurol       Date:  2007-04       Impact factor: 3.685

View more
  31 in total

1.  Plasma Amyloid Beta 1-42 and DNA Methylation Pattern Predict Accelerated Aging in Young Subjects with Down Syndrome.

Authors:  Rima Obeid; Ulrich Hübner; Marion Bodis; Juergen Geisel
Journal:  Neuromolecular Med       Date:  2016-05-27       Impact factor: 3.843

2.  The AT(N) framework for Alzheimer's disease in adults with Down syndrome.

Authors:  Michael S Rafii; Beau M Ances; Nicole Schupf; Sharon J Krinsky-McHale; Mark Mapstone; Wayne Silverman; Ira Lott; William Klunk; Elizabeth Head; Brad Christian; Florence Lai; H Diana Rosas; Shahid Zaman; Melissa E Petersen; Andre Strydom; Juan Fortea; Benjamin Handen; Sid O'Bryant
Journal:  Alzheimers Dement (Amst)       Date:  2020-10-27

3.  Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP.

Authors:  Eric Doran; David Keator; Elizabeth Head; Michael J Phelan; Ron Kim; Minodora Totoiu; Jorge R Barrio; Gary W Small; Steven G Potkin; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  Is Apolipoprotein E4 an Important Risk Factor for Dementia in Persons with Down Syndrome?

Authors:  Troy T Rohn; Katie L McCarty; Julia E Love; Elizabeth Head
Journal:  J Parkinsons Dis Alzheimers Dis       Date:  2014-12-08

Review 5.  Neurological phenotypes for Down syndrome across the life span.

Authors:  Ira T Lott
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

6.  Brain Perivascular Macrophages Initiate the Neurovascular Dysfunction of Alzheimer Aβ Peptides.

Authors:  Laibaik Park; Ken Uekawa; Lidia Garcia-Bonilla; Kenzo Koizumi; Michelle Murphy; Rose Pistik; Linda Younkin; Steven Younkin; Ping Zhou; George Carlson; Josef Anrather; Costantino Iadecola
Journal:  Circ Res       Date:  2017-05-17       Impact factor: 17.367

Review 7.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

8.  Brain and circulating levels of Aβ1-40 differentially contribute to vasomotor dysfunction in the mouse brain.

Authors:  Laibaik Park; Ping Zhou; Kenzo Koizumi; Sleiman El Jamal; Mary Lou Previti; William E Van Nostrand; George Carlson; Costantino Iadecola
Journal:  Stroke       Date:  2012-11-29       Impact factor: 7.914

9.  Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain.

Authors:  Fabio Di Domenico; Raffaella Coccia; Annalisa Cocciolo; M Paul Murphy; Giovanna Cenini; Elizabeth Head; D Allan Butterfield; Alessandra Giorgi; Maria Eugenia Schinina; Cesare Mancuso; Chiara Cini; Marzia Perluigi
Journal:  Biochim Biophys Acta       Date:  2013-04-18

10.  Alzheimer's Disease in Down Syndrome.

Authors:  Elizabeth Head; David Powell; Brian T Gold; Frederick A Schmitt
Journal:  Eur J Neurodegener Dis       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.